However, the introduction of disease-modifying treatments for CF has dramatically changed the prognosis and quality of life of CF patients. These treatments have now been approved for children as young as two years of age. Early modulator therapy in the first years of life has the potential to prevent the development of lung disease and dramatically alter the course of their lives.
We have a scholarship opportunity for a PhD project to determine the lung health trajectories of children with CF in WA and investigate the impact of early life disease-modifying treatments on lung health outcomes in early childhood.
LI-DNI
Phd Scholarship • Australia